{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:41:02Z","timestamp":1786981262247,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10928-018-9609-6","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T11:27:06Z","timestamp":1540898826000},"page":"817-827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A pre-clinical quantitative model predicts the pharmacokinetics\/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans"],"prefix":"10.1007","volume":"45","author":[{"given":"Konstantinos","family":"Biliouris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Nestorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Pellerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Rabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence J.","family":"Lesko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam N.","family":"Trame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"issue":"22","key":"9609_CR1","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365(22):2110\u20132121","journal-title":"N Engl J Med"},{"issue":"2","key":"9609_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/35100573","volume":"1","author":"MJ Shlomchik","year":"2001","unstructured":"Shlomchik MJ, Craft JE, Mamula MJ (2001) From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 1(2):147\u2013153","journal-title":"Nat Rev Immunol"},{"issue":"7300","key":"9609_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nature09102","volume":"465","author":"C Guiducci","year":"2010","unstructured":"Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, Chan JH, Wright T, Punaro M, Bolland S, Soumelis VTLR (2010) Recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465(7300):937\u2013941","journal-title":"Nature"},{"issue":"6","key":"9609_CR4","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.immuni.2010.11.025","volume":"33","author":"LL Teichmann","year":"2010","unstructured":"Teichmann LL, Ols ML, Kashgarian M, Reizis B, Kaplan DH, Shlomchik MJ (2010) Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 33(6):967\u2013978","journal-title":"Immunity"},{"issue":"6","key":"9609_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.coi.2012.10.004","volume":"24","author":"J Choi","year":"2012","unstructured":"Choi J, Kim ST, Craft J (2012) The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol 24(6):651\u2013657","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"9609_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrd3436","volume":"10","author":"I Sanz","year":"2011","unstructured":"Sanz I, Yasothan U, Kirkpatrick P (2011) Belimumab. Nat Rev Drug Discov. 10(5):335\u2013336","journal-title":"Nat Rev Drug Discov."},{"issue":"17","key":"9609_CR7","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1001\/jama.2011.548","volume":"305","author":"M Mitka","year":"2011","unstructured":"Mitka M (2011) Treatment for lupus, first in 50\u00a0years, offers modest benefits, hope to patients. JAMA 305(17):1754\u20131755","journal-title":"JAMA"},{"issue":"5","key":"9609_CR8","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","volume":"100","author":"EC Baechler","year":"2003","unstructured":"Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100(5):2610\u20132615","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"9609_CR9","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1177\/0961203309105529","volume":"18","author":"M Petri","year":"2009","unstructured":"Petri M, Singh S, Tesfasyone H, Dedrick R, Fry K, Lal P, Williams G, Bauer JW, Gregersen PK, Behrens TW, Baechler EC (2009) Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus. 18(11):980\u2013989","journal-title":"Lupus."},{"key":"9609_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fimmu.2012.00233","volume":"3","author":"G Amodio","year":"2012","unstructured":"Amodio G, Gregori S (2012) Dendritic cells a double-edge sword in autoimmune responses. Front Immunol. 3:233","journal-title":"Front Immunol."},{"issue":"10","key":"9609_CR11","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1084\/jem.20132620","volume":"211","author":"SL Rowland","year":"2014","unstructured":"Rowland SL, Riggs JM, Gilfillan S, Bugatti M, Vermi W, Kolbeck R, Unanue ER, Sanjuan MA, Colonna M (2014) Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model. J Exp Med 211(10):1977\u20131991","journal-title":"J Exp Med"},{"issue":"4","key":"9609_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.15252\/emmm.201404719","volume":"7","author":"A Pellerin","year":"2015","unstructured":"Pellerin A, Otero K, Czerkowicz JM, Kerns HM, Shapiro RI, Ranger AM, Otipoby KL, Taylor FR, Cameron TO, Viney JL, Rabah D (2015) Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med. 7(4):464\u2013476","journal-title":"EMBO Mol Med."},{"issue":"10","key":"9609_CR13","doi-asserted-by":"publisher","first-page":"e248","DOI":"10.1371\/journal.pbio.0050248","volume":"5","author":"W Cao","year":"2007","unstructured":"Cao W, Zhang L, Rosen DB, Bover L, Watanabe G, Bao M, Lanier LL, Liu YJ (2007) BDCA2\/Fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. PLoS Biol 5(10):e248","journal-title":"PLoS Biol"},{"issue":"12","key":"9609_CR14","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1084\/jem.194.12.1823","volume":"194","author":"A Dzionek","year":"2001","unstructured":"Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F, G\u00fcnther G, Johnston I, Lanzavecchia A, Nagasaka T, Okada T (2001) BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha\/beta induction. J Exp Med 194(12):1823\u20131834","journal-title":"J Exp Med"},{"issue":"9","key":"9609_CR15","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.4049\/jimmunol.177.9.5829","volume":"177","author":"SL Fanning","year":"2006","unstructured":"Fanning SL, George TC, Feng D, Feldman SB, Megjugorac NJ, Izaguirre AG, Fitzgerald-Bocarsly P (2006) Receptor cross-linking on human plasmacytoid dendritic cells leads to the regulation of IFN-alpha production. J Immunol 177(9):5829\u20135839","journal-title":"J Immunol"},{"issue":"12","key":"9609_CR16","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1002\/eji.200737711","volume":"37","author":"J R\u00f6ck","year":"2007","unstructured":"R\u00f6ck J, Schneider E, Gr\u00fcn JR, Gr\u00fctzkau A, K\u00fcppers R, Schmitz J, Winkels G (2007) CD303 (BDCA-2) signals in plasmacytoid dendritic cells via a BCR-like signalosome involving Syk, Slp65 and PLCgamma2. Eur J Immunol 37(12):3564\u20133575","journal-title":"Eur J Immunol"},{"issue":"6","key":"9609_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1023\/A:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28(6):507\u2013532","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"9609_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1208\/s12248-014-9690-8","volume":"17","author":"AP Singh","year":"2015","unstructured":"Singh AP, Krzyzanski W, Martin SW, Weber G, Betts A, Ahmad A, Abraham A, Zutshi A, Lin J, Singh P (2015) Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. AAPS J 17(2):389\u2013399","journal-title":"AAPS J"},{"issue":"12","key":"9609_CR19","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1177\/0091270009337134","volume":"49","author":"J Ling","year":"2009","unstructured":"Ling J, Zhou H, Jiao Q, Davis HM (2009) Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 49(12):1382\u20131402","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"9609_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4161\/mabs.3.1.13799","volume":"3","author":"R Deng","year":"2011","unstructured":"Deng R, Iyer S, Theil F-P, Mortensen DL, Fielder PJ, Prabhu S (2011) Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 3(1):61\u201366","journal-title":"MAbs"},{"issue":"4","key":"9609_CR21","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1208\/s12248-010-9236-7","volume":"12","author":"JP Gibbs","year":"2010","unstructured":"Gibbs JP (2010) Prediction of exposure\u2013response relationships to support first-in-human study design. AAPS J 12(4):750\u2013758","journal-title":"AAPS J"},{"issue":"2","key":"9609_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2165\/11537430-000000000-00000","volume":"50","author":"JQ Dong","year":"2011","unstructured":"Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu C-P, Stouch BJ, Hurh E, Gibbs M (2011) Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 50(2):131\u2013142","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"9609_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10928-014-9401-1","volume":"42","author":"VL Chudasama","year":"2015","unstructured":"Chudasama VL, Zutshi A, Singh P, Abraham AK, Mager DE, Harrold JM (2015) Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies. J Pharmacokinet Pharmacodyn 42(1):1\u201318","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"9609_CR24","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40262-013-0085-2","volume":"52","author":"R Narwal","year":"2013","unstructured":"Narwal R, Roskos LK, Robbie GJ (2013) Population pharmacokinetics of sifalimumab, an investigational anti-interferon-\u03b1 monoclonal antibody, in systemic lupus erythematosus. Clin Pharmacokinet 52(11):1017\u20131027","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"9609_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/clpt.2013.35","volume":"93","author":"B Wang","year":"2013","unstructured":"Wang B, Higgs BW, Chang L, Vainshtein I, Liu Z, Streicher K, Liang M, White WI, Yoo S, Richman L, Jallal B (2013) Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-\u03b1 receptor antibody. Clin Pharmacol Ther 93(6):483\u2013492","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"9609_CR26","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/bcp.12864","volume":"81","author":"B Zheng","year":"2015","unstructured":"Zheng B, Yu X-Q, Greth W, Robbie GJ (2015) Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients. Br J Clin Pharmacol 81(5):918\u2013928","journal-title":"Br J Clin Pharmacol"},{"key":"9609_CR27","volume-title":"NONMEM user\u2019s guides","author":"S Beal","year":"2009","unstructured":"Beal S, Sheiner L, Bauer R (2009) NONMEM user\u2019s guides. Icon Development Solutions, Ellicott City"},{"issue":"4","key":"9609_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/BF01061691","volume":"21","author":"NL Dayneka","year":"1993","unstructured":"Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21(4):457\u2013478","journal-title":"J Pharmacokinet Biopharm"},{"issue":"9","key":"9609_CR29","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/psp4.12011","volume":"4","author":"K Biliouris","year":"2015","unstructured":"Biliouris K, Lavielle M, Trame MN (2015) MatVPC: a user-friendly MATLAB-based tool for the simulation and evaluation of systems pharmacology models. CPT Pharmacomet Syst Pharmacol. 4(9):547\u2013557","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"issue":"3","key":"9609_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN, Jonsson N (2005) PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79(3):241\u2013257","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"9609_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/psp4.6","volume":"4","author":"XY Zhang","year":"2015","unstructured":"Zhang XY, Trame MN, Lesko LJ, Schmidt S (2015) Sobol sensitivity analysis: a tool to guide the development and evaluation of systems pharmacology models. CPT Pharmacometrics Syst Pharmacol 4(2):69\u201379","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"9609_CR32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1177\/1087057109336751","volume":"14","author":"BF Krippendorff","year":"2009","unstructured":"Krippendorff BF, Neuhaus R, Lienau P, Reichel A, Huisinga W (2009) Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values. J Biomol Screen 14(8):913\u2013923","journal-title":"J Biomol Screen"},{"issue":"12","key":"9609_CR33","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1007\/s11095-014-1416-1","volume":"31","author":"L Kagan","year":"2014","unstructured":"Kagan L, Zhao J, Mager DE (2014) Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. Pharm Res 31(12):3265\u20133273","journal-title":"Pharm Res"},{"issue":"3","key":"9609_CR34","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2133\/dmpk.DMPK-11-SH-059","volume":"27","author":"M Oitate","year":"2012","unstructured":"Oitate M, Nakayama S, Ito T, Kurihara A, Okudaira N, Izumi T (2012) Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method. Drug Metab Pharmacokinet 27(3):354\u2013359","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"9609_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2133\/dmpk.DMPK-11-RG-011","volume":"26","author":"M Oitate","year":"2011","unstructured":"Oitate M, Masubuchi N, Ito T, Yabe Y, Karibe T, Aoki T, Murayama N, Kurihara A, Okudaira N, Izumi T (2011) Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. Drug Metab Pharmacokinet 26(4):423\u2013430","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"9609_CR36","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s11095-010-0098-6","volume":"27","author":"L Kagan","year":"2010","unstructured":"Kagan L, Abraham AK, Harrold JM, Mager DE (2010) Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res 27(5):920\u2013932","journal-title":"Pharm Res"},{"issue":"3","key":"9609_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/clpt.2008.273","volume":"85","author":"PY Muller","year":"2009","unstructured":"Muller PY, Brennan FR (2009) Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Ther 85(3):247\u2013258","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"9609_CR38","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.copbio.2009.10.013","volume":"20","author":"PY Muller","year":"2009","unstructured":"Muller PY, Milton M, Lloyd P, Sims J, Brennan FR (2009) The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Opin Biotechnol 20(6):722\u2013729","journal-title":"Curr Opin Biotechnol"},{"issue":"2","key":"9609_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1517\/17425255.2012.643868","volume":"8","author":"R Deng","year":"2012","unstructured":"Deng R, Jin F, Prabhu S, Iyer S (2012) Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol. 8(2):141\u2013160","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"3","key":"9609_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1742-7843.2009.00513.x","volume":"106","author":"PJ Lowe","year":"2010","unstructured":"Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J (2010) On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol 106(3):195\u2013209","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"9609_CR41","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1124\/jpet.112.191999","volume":"341","author":"KT Luu","year":"2012","unstructured":"Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E (2012) A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther 341(3):702\u2013708","journal-title":"J Pharmacol Exp Ther"},{"key":"9609_CR42","unstructured":"Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus [Internet]. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02106897\n                    \n                  . Cited 5 May 2016"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-018-9609-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T16:52:24Z","timestamp":1572454344000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-018-9609-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["9609"],"URL":"https:\/\/doi.org\/10.1007\/s10928-018-9609-6","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,30]]},"assertion":[{"value":"30 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}